MX349484B - Compuesto heterocíclico saturado que contiene nitrógeno. - Google Patents

Compuesto heterocíclico saturado que contiene nitrógeno.

Info

Publication number
MX349484B
MX349484B MX2013010554A MX2013010554A MX349484B MX 349484 B MX349484 B MX 349484B MX 2013010554 A MX2013010554 A MX 2013010554A MX 2013010554 A MX2013010554 A MX 2013010554A MX 349484 B MX349484 B MX 349484B
Authority
MX
Mexico
Prior art keywords
denotes
nitrogen
saturated heterocyclic
heterocyclic compound
containing saturated
Prior art date
Application number
MX2013010554A
Other languages
English (en)
Other versions
MX2013010554A (es
Inventor
Takayuki Kawaguchi
Hiroshi Sugama
Jingkang Shen
Guangxin Xia
Jianshu Xie
Toru Iijima
Hirai Miki
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2013010554A publication Critical patent/MX2013010554A/es
Publication of MX349484B publication Critical patent/MX349484B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona un compuesto heterocídilco saturado que contiene nitrógeno de la fórmula [I]: (Ver Formula) en donde R1 es un grupo cicloalquilo y similares, R22 es un arilo opcionalmente sustituido y similares, R es un alquilo inferior y similares, T es un grupo carbonilo, Z es -O- y similares, y R3 a R6 son iguales o diferentes y son un átomo de hidrógeno y similares; o una sal farmacéuticamente aceptable, que es útil como un inhibidor de renina.
MX2013010554A 2011-03-16 2012-03-15 Compuesto heterocíclico saturado que contiene nitrógeno. MX349484B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011058338 2011-03-16
PCT/JP2012/056750 WO2012124775A1 (ja) 2011-03-16 2012-03-15 含窒素飽和複素環化合物

Publications (2)

Publication Number Publication Date
MX2013010554A MX2013010554A (es) 2013-12-02
MX349484B true MX349484B (es) 2017-07-31

Family

ID=46830839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010554A MX349484B (es) 2011-03-16 2012-03-15 Compuesto heterocíclico saturado que contiene nitrógeno.

Country Status (17)

Country Link
US (2) US9278944B2 (es)
EP (1) EP2687518B1 (es)
JP (1) JP5760078B2 (es)
KR (1) KR101651722B1 (es)
CN (1) CN103562191B (es)
AU (1) AU2012229859C1 (es)
BR (1) BR112013023480B1 (es)
CA (1) CA2828378C (es)
DK (1) DK2687518T3 (es)
ES (1) ES2652454T3 (es)
HU (1) HUE037584T2 (es)
MX (1) MX349484B (es)
PL (1) PL2687518T3 (es)
PT (1) PT2687518T (es)
RU (1) RU2595136C2 (es)
TW (1) TWI597273B (es)
WO (1) WO2012124775A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5764628B2 (ja) * 2012-09-14 2015-08-19 田辺三菱製薬株式会社 医薬組成物
CN104640847B (zh) * 2012-09-14 2019-10-15 上海医药集团股份有限公司 新型肾素抑制剂
CN113816952A (zh) * 2015-12-29 2021-12-21 上海医药集团股份有限公司 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN109705052B (zh) * 2019-01-25 2020-12-08 苏州大学 一种制备1,4-二氢噁嗪的方法
WO2022048614A1 (zh) 2020-09-04 2022-03-10 上海医药集团股份有限公司 一种含氮的饱和杂环化合物的应用
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0505969D0 (en) * 2005-03-23 2005-04-27 Novartis Ag Organic compounds
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN104640847B (zh) * 2012-09-14 2019-10-15 上海医药集团股份有限公司 新型肾素抑制剂

Also Published As

Publication number Publication date
EP2687518A1 (en) 2014-01-22
MX2013010554A (es) 2013-12-02
CN103562191B (zh) 2016-03-30
BR112013023480A2 (pt) 2017-07-18
KR20130133294A (ko) 2013-12-06
BR112013023480B1 (pt) 2019-10-01
AU2012229859C1 (en) 2020-01-16
TWI597273B (zh) 2017-09-01
HUE037584T2 (hu) 2018-09-28
JPWO2012124775A1 (ja) 2014-07-24
US9278944B2 (en) 2016-03-08
US10155731B2 (en) 2018-12-18
JP5760078B2 (ja) 2015-08-05
PT2687518T (pt) 2018-01-19
US20140011807A1 (en) 2014-01-09
AU2012229859B2 (en) 2015-07-16
KR101651722B1 (ko) 2016-08-26
CN103562191A (zh) 2014-02-05
EP2687518A4 (en) 2014-08-20
TW201242955A (en) 2012-11-01
AU2012229859A1 (en) 2013-09-19
DK2687518T3 (da) 2018-01-29
BR112013023480A8 (pt) 2019-07-09
PL2687518T3 (pl) 2018-04-30
CA2828378C (en) 2017-11-14
RU2013146012A (ru) 2015-05-27
EP2687518B1 (en) 2017-11-01
US20160145220A1 (en) 2016-05-26
RU2595136C2 (ru) 2016-08-20
CA2828378A1 (en) 2012-09-20
WO2012124775A1 (ja) 2012-09-20
ES2652454T3 (es) 2018-02-02

Similar Documents

Publication Publication Date Title
IN2014MN01897A (es)
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
CA2875877C (en) Syk inhibitors
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
MX349484B (es) Compuesto heterocíclico saturado que contiene nitrógeno.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
JO3116B1 (ar) مشتق بيرازولوكينولين كمثبطات ل pde9
MX2016006336A (es) Compuestos pirazolopirimidina.
MX2015012062A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MX2013011429A (es) Novedoso compuesto de imidazo-oxazina o sal del mismo.
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
NZ608285A (en) Manufacturing process for pyrimidine derivatives
MX2014000452A (es) Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk).
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
RS54730B1 (sr) Inhibitori beta sekretaze
IN2014DN07509A (es)
NZ712352A (en) Novel inhibitors of glutaminyl cyclase
JO3318B1 (ar) مثبطات bace
TW201129558A (en) Piperazine compound having a pgds inhibitory effect
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
RS53900B1 (en) CRYSTAL FORMS OF HYDROCHLORIDE SALTS (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONYL) -2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDENO [2,1-B] PIRIDIN-6-CARBONITRILA AND THEIR USE AS A HSD INHIBITOR 1
GB201101517D0 (en) Receptor antagonists
GB201305247D0 (en) Amide Compounds

Legal Events

Date Code Title Description
FG Grant or registration